Bruce Willis’ family has made public an important and deeply personal decision: after the actor’s death, his brain will be donated to the scientific community for studies on frontotemporal dementia. The announcement shifts attention to a rare and progressive disease for which treatments that can stop it are still lacking.
The decision was made public by Emma Heming
The decision was made by the actor’s wife, Emma Heming, after discussions with their daughters and with Willis’ former wife, Demi Moore.
The details were made known in Heming’s book, The Unexpected Journey, in which she recounts the family’s confrontation with the disease and the reasons that led them to this choice.
A painful choice aimed at scientific research
According to what Heming has explained publicly, this is an emotionally very difficult decision, but one the family considers useful for medical research.
Through this donation, researchers are expected to have the opportunity to analyze changes in the brain and to understand more clearly how frontotemporal dementia progresses, with the hope of more effective treatments in the future.
Bruce Willis’ diagnosis and the progression of the disease
Bruce Willis, 71, was diagnosed with frontotemporal dementia in 2023, after it had earlier been made public that he was suffering from aphasia, a disorder that affects communication.
Frontotemporal dementia is a progressive neurodegenerative disease and, so far, there is no cure that can stop it.
Anosognosia is also part of his condition
In January, Emma Heming also spoke about another aspect of the actor’s condition, revealing that he suffers from anosognosia.
This neurological disorder means that a person is unable to fully understand or recognize the illness affecting them, making the day-to-day burden of the diagnosis even more difficult.
For some time, Bruce Willis’ family has publicly shared the difficulties this illness brings to daily life.
Now, through this decision, it is trying to ensure that a painful personal experience also has concrete value for the study of frontotemporal dementia.